Trial Profile
A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2025
Price :
$35
*
At a glance
- Drugs Alectinib (Primary) ; Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cobimetinib (Primary) ; Entrectinib (Primary) ; Erlotinib (Primary) ; Ipatasertib (Primary) ; Olaparib (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Vemurafenib (Primary) ; Vismodegib (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Ivosidenib; Paclitaxel; Pemigatinib
- Indications Adenocarcinoma; Cancer; Carcinoma
- Focus Therapeutic Use
- Acronyms CUPISCO
- Sponsors Roche
Most Recent Events
- 04 Feb 2025 Status changed from active, no longer recruiting to completed.
- 24 Sep 2024 This trial has been completed in Austria, according to European Clinical Trials Database record.
- 18 Sep 2024 This trial has been completed in Finland, according to European Clinical Trials Database record.